These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

525 related items for PubMed ID: 9510219

  • 1. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol.
    Tollefson GD, Sanger TM, Lu Y, Thieme ME.
    Arch Gen Psychiatry; 1998 Mar; 55(3):250-8. PubMed ID: 9510219
    [Abstract] [Full Text] [Related]

  • 2. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
    Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME.
    Am J Psychiatry; 1997 Apr; 154(4):457-65. PubMed ID: 9090331
    [Abstract] [Full Text] [Related]

  • 3. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia.
    Breier A, Hamilton SH.
    Biol Psychiatry; 1999 Feb 15; 45(4):403-11. PubMed ID: 10071708
    [Abstract] [Full Text] [Related]

  • 4. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.
    Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, McEvoy J, Perkins D, Sharma T, Zipursky R, Wei H, Hamer RM, HGDH Study Group.
    Am J Psychiatry; 2003 Aug 15; 160(8):1396-404. PubMed ID: 12900300
    [Abstract] [Full Text] [Related]

  • 5. Anxious-depressive symptoms in schizophrenia: a new treatment target for pharmacotherapy?
    Tollefson GD, Sanger TM.
    Schizophr Res; 1999 Mar 01; 35 Suppl():S13-21. PubMed ID: 10190222
    [Abstract] [Full Text] [Related]

  • 6. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine.
    Tollefson GD, Sanger TM.
    Am J Psychiatry; 1997 Apr 01; 154(4):466-74. PubMed ID: 9090332
    [Abstract] [Full Text] [Related]

  • 7. Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial.
    Gomez JC, Crawford AM.
    J Clin Psychiatry; 2001 Apr 01; 62 Suppl 2():6-11. PubMed ID: 11232753
    [Abstract] [Full Text] [Related]

  • 8. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.
    Lindenmayer JP, Khan A, Iskander A, Abad MT, Parker B.
    J Clin Psychiatry; 2007 Mar 01; 68(3):368-79. PubMed ID: 17388705
    [Abstract] [Full Text] [Related]

  • 9. Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia.
    Kinon BJ, Roychowdhury SM, Milton DR, Hill AL.
    J Clin Psychiatry; 2001 Mar 01; 62 Suppl 2():17-21. PubMed ID: 11232746
    [Abstract] [Full Text] [Related]

  • 10. Olanzapine: an updated review of its use in the management of schizophrenia.
    Bhana N, Foster RH, Olney R, Plosker GL.
    Drugs; 2001 Mar 01; 61(1):111-61. PubMed ID: 11217867
    [Abstract] [Full Text] [Related]

  • 11. Olanzapine versus haloperidol treatment in first-episode psychosis.
    Sanger TM, Lieberman JA, Tohen M, Grundy S, Beasley C, Tollefson GD.
    Am J Psychiatry; 1999 Jan 01; 156(1):79-87. PubMed ID: 9892301
    [Abstract] [Full Text] [Related]

  • 12. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
    Ascher-Svanum H, Stensland M, Zhao Z, Kinon BJ.
    BMC Psychiatry; 2005 Jan 13; 5():3. PubMed ID: 15649317
    [Abstract] [Full Text] [Related]

  • 13. A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia.
    Tollefson GD, Sanger TM, Beasley CM, Tran PV.
    Biol Psychiatry; 1998 Jun 01; 43(11):803-10. PubMed ID: 9611669
    [Abstract] [Full Text] [Related]

  • 14. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.
    Lindenmayer JP, Czobor P, Volavka J, Lieberman JA, Citrome L, Sheitman B, Chakos M, McEvoy JP.
    J Clin Psychiatry; 2002 Oct 01; 63(10):931-5. PubMed ID: 12416603
    [Abstract] [Full Text] [Related]

  • 15. The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone.
    Tollefson GD, Andersen SW, Tran PV.
    Biol Psychiatry; 1999 Aug 01; 46(3):365-73. PubMed ID: 10435202
    [Abstract] [Full Text] [Related]

  • 16. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia.
    Tran PV, Dellva MA, Tollefson GD, Beasley CM, Potvin JH, Kiesler GM.
    J Clin Psychiatry; 1997 May 01; 58(5):205-11. PubMed ID: 9184614
    [Abstract] [Full Text] [Related]

  • 17. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study.
    de Haan L, van Bruggen M, Lavalaye J, Booij J, Dingemans PM, Linszen D.
    Am J Psychiatry; 2003 Feb 01; 160(2):303-9. PubMed ID: 12562577
    [Abstract] [Full Text] [Related]

  • 18. Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?
    Tollefson GD, Andersen SW.
    J Clin Psychiatry; 1999 Feb 01; 60 Suppl 5():23-9; discussion 30. PubMed ID: 10192404
    [Abstract] [Full Text] [Related]

  • 19. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
    Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Cooper TB, Chakos M, Lieberman JA.
    Am J Psychiatry; 2002 Feb 01; 159(2):255-62. PubMed ID: 11823268
    [Abstract] [Full Text] [Related]

  • 20. Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial.
    Ishigooka J, Inada T, Miura S.
    Psychiatry Clin Neurosci; 2001 Aug 01; 55(4):403-14. PubMed ID: 11442893
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.